Obstet Gynecol Sci.  2023 Nov;66(6):477-483. 10.5468/ogs.22270.

The effect of a vanishing twin on first- and second-trimester maternal serum markers and ultrasound screening for aneuploidy

• Lee DR
• Lee S
• Lee SJ

• KMID: 2547849
• DOI: http://doi.org/10.5468/ogs.22270

Abstract

A vanishing twin (VT) is the early demise of a twin fetus. It is estimated to occur in 20-30% of pregnancies associated with assisted reproductive technology. VT becomes increasingly prominent when assisted fertilization is used, because one or more embryos are transferred to the uterus. Maternal serum screening tests during pregnancy can screen for trisomy chromosomes 21, 18, and 13 and are divided into first- and second-trimester tests. In singleton pregnancies, the first trimester screening test is performed at 11-13 weeks and 6 days of gestation. It consists of two serum markers, pregnancy-associated plasma protein A and β-human chorionic gonadotropin (β-hCG), and measures nuchal translucency thickness. The second-trimester screening test was performed at 15-20 weeks and 6 days of gestation. It consists of four serum markers: alpha-fetoprotein, β-hCG, unconjugated estriol, and inhibin A. More effective screening for trisomy 21 in singleton pregnancies is achieved by analyzing cell-free DNA in the maternal blood. A VT includes a demise of the fetus. Although it affects maternal serum markers, it has not been corrected. Five studies examined the effect of VT on maternal serum markers, but the results were controversial. This study aimed to review the patterns of changes in maternal serum markers in VTs, interpret prenatal tests for pregnant women with VTs in clinical practice, and consider what information should be provided.

Keyword

Prenatal diagnosis; Down syndrome; Aneuploidy; Pregnancy-associated plasma protein-A; Chorionic gonadotropin

Reference

References

1. Bókkon I, Vas JP, Császár N, Lukács T. Challenges to free will: transgenerational epigenetic information, unconscious processes, and vanishing twin syndrome. Rev Neurosci. 2014; 25:163–75.

2. Magnus MC, Ghaderi S, Morken NH, Magnus P, Bente Romundstad L, Skjærven R, et al. Vanishing twin syndrome among ART singletons and pregnancy outcomes. Hum Reprod. 2017; 32:2298–304.

3. Gjerris AC, Loft A, Pinborg A, Christiansen M, Tabor A. The effect of a ‘vanishing twin’ on biochemical and ultrasound first trimester screening markers for Down’s syndrome in pregnancies conceived by assisted reproductive technology. Hum Reprod. 2009; 24:55–62.

4. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins. Screening for fetal chromosomal abnormalities: ACOG practice bulletin, number 226. Obstet Gynecol. 2020; 136:e48–69.

5. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med. 2005; 353:2001–11.

6. Spencer K, Nicolaides KH. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG. 2003; 110:276–80.

7. Huang T, Boucher K, Aul R, Rashid S, Meschino WS. First and second trimester maternal serum markers in pregnancies with a vanishing twin. Prenat Diagn. 2015; 35:90–6.

8. Leguy MC, Brun S, Pidoux G, Salhi H, Choiset A, Menet MC, et al. Pattern of secretion of pregnancy-associated plasma protein-A (PAPP-A) during pregnancies complicated by fetal aneuploidy, in vivo and in vitro. Reprod Biol Endocrinol. 2014; 12:129.

9. Handschuh K, Guibourdenche J, Guesnon M, Laurendeau I, Evain-Brion D, Fournier T. Modulation of PAPP-A expression by PPARgamma in human first trimester trophoblast. Placenta. 2006; 27(Suppl A):S127–34.

10. Chasen ST, Perni SC, Predanic M, Kalish RB, Chervenak FA. Does a “vanishing twin” affect first-trimester biochemistry in Down syndrome risk assessment? Am J Obstet Gynecol. 2006; 195:236–9.

11. Spencer K, Staboulidou I, Nicolaides KH. First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers. Prenat Diagn. 2010; 30:235–40.

12. Chaveeva P, Wright A, Syngelaki A, Konstantinidou L, Wright D, Nicolaides KH. First-trimester screening for trisomies in pregnancies with vanishing twin. Ultrasound Obstet Gynecol. 2020; 55:326–31.

13. Shiefa S, Amargandhi M, Bhupendra J, Moulali S, Kristine T. First trimester maternal serum screening using biochemical markers PAPP-A and free β-hCG for down syndrome, patau syndrome and edward syndrome. Indian J Clin Biochem. 2013; 28:3–12.

14. Tul N, Spencer K, Noble P, Chan C, Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10–14 weeks of gestation. Prenat Diagn. 1999; 19:1035–42.

15. Snijders R, Smith E. The role of fetal nuchal translucency in prenatal screening. Curr Opin Obstet Gynecol. 2002; 14:577–85.

16. Lee SW. Prenatal maternal serum screening for fetal aneuploidy. J Korean Medical Assoc. 2015; 58:989–94.

17. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol. 1984; 148:886–94.

18. Benn PA. Advances in prenatal screening for Down syndrome: I. General principles and second trimester testing. Clin Chim Acta. 2002; 323:1–16.

19. Chen HJ, Huang LW, Lin YH, Seow KM, Hsieh BC, Hwang JL, et al. Midtrimester maternal serum inhibin A levels after multifetal pregnancy reduction. Prenat Diagn. 2007; 27:431–4.

20. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ.  Low second trimester maternal serum unconjugated oestriol in pregnancies with Down’s syndrome. Br J Obstet Gynaecol. 1988; 95:330–3.

21. Lee S, Jung Y, Jisu S, Han Y, Kim M, Shim J, et al. EP07. 01: the effect of vanishing twin on the first and second trimester maternal serum makers and nuchal translucency: a multicentre prospective cohort study. Ultrasound Obstet Gynecol. 2018; 52:219–20.

22. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn. 1987; 7:623–30.

23. Benn P, Rebarber A. Non-invasive prenatal testing in the management of twin pregnancies. Prenat Diagn. 2021; 41:1233–40.

24. Kleinfinger P, Luscan A, Descourvieres L, Buzas D, Boughalem A, Serero S, et al. Noninvasive prenatal screening for trisomy 21 in patients with a vanishing twin. Genes (Basel). 2022; 13:2027.

25. Niles KM, Murji A, Chitayat D. Prolonged duration of persistent cell-free fetal DNA from vanishing twin. Ultrasound Obstet Gynecol. 2018; 52:547–8.

26. Hopkins MK, Dugoff L. Screening for aneuploidy in twins. Am J Obstet Gynecol MFM. 2022; 4:100499.

27. Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2017; 50:302–14.

28. Audibert F, Gagnon A. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies. J Obstet Gynaecol Can. 2011; 33:754–67.

29. Curnow KJ, Wilkins-Haug L, Ryan A, Kırkızlar E, Stosic M, Hall MP, et al. Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphism-based noninvasive prenatal test. Am J Obstet Gynecol. 2015; 212:79e1–9.

30. Balaguer N, Mateu-Brull E, Serra V, Simón C, Milán M. Should vanishing twin pregnancies be systematically excluded from cell-free fetal DNA testing? Prenat Diag. 2021; 41:1241–8.

31. Chang CS, Choi Y, Kim SY, Yee C, Kim M, Sung JH, et al. Prenatal ultrasonographic findings of esophageal atresia: potential diagnostic role of the stomach shape. Obstet Gynecol Sci. 2021; 64:42–51.

32. Ko HS, Kwak DW, Oh SY, Choi SK, Hong JS, Hwang HS, et al. Clinical significance of soft markers in second trimester ultrasonography for pregnant Korean women: a multicenter study and literature review. Obstet Gynecol Sci. 2022; 65:145–55.